Chordia Therapeutics Inc. (190A) Press Release
Announcement Regarding AMED Grant Award for rogocekib (CTX-712)
Earlier from Chordia Therapeutics
- Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib
- Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML
- Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor
- Notice of Receipt of Grant